Tim Eijgenraam
@timeijgenraam
Postdoctoral researcher at the department of Experimental Cardiology of the University Medical Center Groningen
ID: 222216576
https://www.linkedin.com/in/timeijgenraam 02-12-2010 19:53:46
31 Tweet
86 Followers
62 Following
Check out our latest research on phospholamban p.Arg14del cardiomyopathy published in Scientific Reports available via open access nature.com/articles/s4159… Rudolf de Boer Peter van der Meer Bas Boukens J.Peter van Tintelen UMCG Cardiology Research Institute Research UMCG
Check out our new spotlight item on the website about a translational model of PLN cardiomyopathy. #PLN #cardiology #research #scientificreports #nature Scientific Reports Tim Eijgenraam Rudolf de Boer groningencardiology.com/spotlights/pub…
Excited to see that the final open access version of our review article “Current understanding of fibrosis in genetic cardiomyopathies” is now available online: doi.org/10.1016/j.tcm.… Rudolf de Boer UMCG Cardiology Research Institute Research UMCG
The importance of patient registries and biobanks in genetic cardiomyopathy research. Our Hartstichting HCM CVON Dosis program as an example doi.org/10.1007/s12471… Rudolf de Boer Tim Eijgenraam Magdalena Harakalova Freyja van Lint UMCG Cardiology Research Institute Folkert Asselbergs @
Great work by Niels Grote Beverborg & Peter van der Meer and a great team of collaborators published in Nature Communications on the use of ASO against PLN to cure cardiomyopathy UMCG Cardiology Research Institute UMCG Stichting PLN Adam rdcu.be/cwmrR
YIA Basic Science- ✔️ PLN cardiomyopathy is a pathogenic cause of HFrEF Treatment with PLN-ASO, ✔️ reduces PLN protein aggregates and fibrosis ✔️ improves cardiac function and life span, in early and advanced disease #HeartFailure2022 European Society of Cardiology UMCG Cardiology Research Institute Tim Eijgenraam